0001193125-23-202887.txt : 20230803 0001193125-23-202887.hdr.sgml : 20230803 20230803162009 ACCESSION NUMBER: 0001193125-23-202887 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230801 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 231140368 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 8-K 1 d524173d8k.htm 8-K 8-K
false 0001654151 0001654151 2023-08-01 2023-08-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1, 2023

 

 

Deciphera Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38219   30-1003521

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

200 Smith Street, Waltham, Massachusetts   02451
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (781) 209-6400

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class

 

Trading

Symbol

 

Name of exchange

on which registered

Common Stock, $0.01 Par Value   DCPH   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 1, 2023, Daniel L. Flynn, Ph.D., notified Deciphera Pharmaceuticals, Inc. (the “Company”) of his retirement from employment with the Company, effective on December 31, 2023, and his resignation from his position as Executive Vice President, Chief Scientific Officer (“CSO”), effective on the employment commencement date of his successor as CSO, which is expected to be on September 5, 2023 (the “Effective Date”). On August 3, 2023, the Company announced the appointment of Dashyant Dhanak, Ph.D., as the Company’s Executive Vice President, CSO, effective as of the Effective Date.

In connection with his resignation, Dr. Flynn entered into a Transition Agreement with the Company and Deciphera Pharmaceuticals, LLC (the “Transition Agreement”) pursuant to which Dr. Flynn agreed to serve as Senior Advisor to the Company from the Effective Date until December 31, 2023 at his current base salary and benefits. Pursuant to the terms of the Transition Agreement, Dr. Flynn will receive the full amount of his target incentive compensation for 2023, subject to his continued employment as Senior Advisor until December 31, 2023. In addition, contemporaneous with the execution of the Transition Agreement, Dr. Flynn entered into a Consulting Agreement with the Company (the “Consulting Agreement”) pursuant to which Dr. Flynn agreed to serve as a consultant to the Company effective January 1, 2024 from time to time and as requested by the Company. In exchange for his services, the Company will pay Dr. Flynn at an agreed upon hourly rate. The Consulting Agreement will continue to and end on December 31, 2027 unless earlier terminated.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

99.1    Press Release issued by Deciphera Pharmaceuticals, Inc. on August 3, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 3, 2023     DECIPHERA PHARMACEUTICALS, INC.
    By:  

/s/ Steven L. Hoerter

    Name:   Steven L. Hoerter
    Title:   President and Chief Executive Officer
EX-99.1 2 d524173dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of

Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

— Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member —

WALTHAM, Mass.—(BUSINESS WIRE)—August 3, 2023— Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023.

Dr. Dhanak brings over 30 years of experience in pharmaceutical research and development and joins Deciphera from Incyte Corporation where he was Executive Vice President and Chief Scientific Officer.

“On behalf of all my colleagues, I want to thank Dan for his vision to found Deciphera two decades ago as a company dedicated to improving the lives of people with cancer. It has been an honor to work alongside such a trailblazing researcher whose innovations in drug discovery now benefit thousands of cancer patients around the world and have the potential to continue making an impact for years to come thanks to our rich clinical and pre-clinical pipeline developed from the research engine that Dan created,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “We are excited to build on our track record of innovation in drug discovery with the announcement that Dash Dhanak is joining Deciphera as our new Chief Scientific Officer. In addition to broad experience in drug discovery and development, Dash is a proven leader with a track record of advancing innovative oncology agents to the clinic. I look forward to working with Dash to continue to build a strong pipeline of novel therapies at Deciphera.”

“I am unbelievably proud of Deciphera’s progress and accomplishments in the years since I founded the company. We have grown from a small research team into a fully-integrated biotechnology company with capabilities from research to international commercialization, anchored as always by a culture that seeks to drive innovation to help patients as our first priority. Together, we have improved the quality of life for many cancer patients around the world,” said Dr. Flynn. “I am confident that the Company’s discovery and early-stage programs are in excellent hands with Dash, and under his leadership, I know Deciphera will develop additional important new medicines for the treatment of cancer.”

“It’s an honor to continue Dan’s legacy of innovation. I’m thrilled to join Deciphera at this pivotal time as it prepares to become a company with multiple approved medicines,” said Dr. Dhanak. “As Deciphera continues to mature as a commercial company, we remain driven to innovate and to discover new medicines to help patients with cancer.”


LOGO

 

Prior to Deciphera, Dr. Dhanak served as Chief Scientific Officer and Executive Vice President at Incyte Corporation. Before joining Incyte in 2018, Dr. Dhanak was Vice President and Head of Discovery Sciences at Janssen Research & Development, and previously spent 25 years at GlaxoSmithKline in positions of increasing responsibility across multiple disease areas, including his final role as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit. Dr. Dhanak received a B.Sc. in Chemistry from the University of Manchester Institute of Science and Technology and a Ph.D. from the University of London. He completed his postdoctoral research in Natural Product Synthesis at Northwestern University.

In addition, the Company announced today that Ron Squarer has been appointed Chairperson of the Board of Directors. Mr. Squarer has over 30 years of experience in the pharmaceutical and biotechnology industry and joined Deciphera as a Director in December 2019. Mr. Squarer served as Chief Executive Officer and a member of the board of directors of Array BioPharma, Inc. from 2012 until its acquisition by Pfizer Inc. in August 2019 following the successful commercial launches of both Braftovi® and Mektovi®. James A. Bristol, Ph.D., who has served as either Chairperson or Co-Chairperson since 2007, will remain a Board member of Deciphera.

“I want to recognize Jim Bristol’s tremendous leadership as Chairperson of the Deciphera board for over 15 years. Jim’s deep industry expertise has been invaluable in guiding our research activities, scaling our organization, and transforming Deciphera into a leading commercial-stage oncology company. We thank him for his exceptional stewardship as Chairperson and look forward to his continued contributions as a member of the board,” said Mr. Hoerter.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the ability for Deciphera to develop additional important new medicines for the treatment of cancer and to become a company with multiple approved medicines. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates,


LOGO

 

the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

The Deciphera logo and the QINLOCK® word mark and logo are registered trademarks and the Deciphera word mark is a trademark of Deciphera Pharmaceuticals, LLC.

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

EX-101.SCH 3 dcph-20230801.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 dcph-20230801_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 dcph-20230801_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g524173g0801232536917.jpg GRAPHIC begin 644 g524173g0801232536917.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 01, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001654151
Document Type 8-K
Document Period End Date Aug. 01, 2023
Entity Registrant Name Deciphera Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38219
Entity Tax Identification Number 30-1003521
Entity Address, Address Line One 200 Smith Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (781)
Local Phone Number 209-6400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 Par Value
Trading Symbol DCPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d524173d8k_htm.xml IDEA: XBRL DOCUMENT 0001654151 2023-08-01 2023-08-01 false 0001654151 8-K 2023-08-01 Deciphera Pharmaceuticals, Inc. DE 001-38219 30-1003521 200 Smith Street Waltham MA 02451 (781) 209-6400 false false false false Common Stock, $0.01 Par Value DCPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d524173d8k.htm d524173dex991.htm dcph-20230801.xsd dcph-20230801_lab.xml dcph-20230801_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d524173d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d524173d8k.htm" ] }, "labelLink": { "local": [ "dcph-20230801_lab.xml" ] }, "presentationLink": { "local": [ "dcph-20230801_pre.xml" ] }, "schema": { "local": [ "dcph-20230801.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dcph", "nsuri": "http://www.deciphera.com/20230801", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d524173d8k.htm", "contextRef": "duration_2023-08-01_to_2023-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d524173d8k.htm", "contextRef": "duration_2023-08-01_to_2023-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.deciphera.com//20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-202887-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-202887-xbrl.zip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end